全文获取类型
收费全文 | 1422篇 |
免费 | 174篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 54篇 |
妇产科学 | 46篇 |
基础医学 | 204篇 |
口腔科学 | 52篇 |
临床医学 | 229篇 |
内科学 | 247篇 |
皮肤病学 | 26篇 |
神经病学 | 195篇 |
特种医学 | 97篇 |
外科学 | 145篇 |
综合类 | 24篇 |
预防医学 | 105篇 |
眼科学 | 12篇 |
药学 | 102篇 |
1篇 | |
肿瘤学 | 38篇 |
出版年
2021年 | 17篇 |
2020年 | 9篇 |
2019年 | 19篇 |
2018年 | 20篇 |
2017年 | 13篇 |
2016年 | 15篇 |
2015年 | 38篇 |
2014年 | 45篇 |
2013年 | 57篇 |
2012年 | 64篇 |
2011年 | 61篇 |
2010年 | 50篇 |
2009年 | 39篇 |
2008年 | 46篇 |
2007年 | 49篇 |
2006年 | 44篇 |
2005年 | 53篇 |
2004年 | 39篇 |
2003年 | 45篇 |
2002年 | 25篇 |
2001年 | 43篇 |
2000年 | 30篇 |
1999年 | 31篇 |
1998年 | 36篇 |
1997年 | 35篇 |
1996年 | 42篇 |
1995年 | 26篇 |
1994年 | 31篇 |
1993年 | 19篇 |
1992年 | 24篇 |
1991年 | 47篇 |
1990年 | 37篇 |
1989年 | 16篇 |
1988年 | 36篇 |
1987年 | 22篇 |
1986年 | 29篇 |
1985年 | 28篇 |
1984年 | 21篇 |
1983年 | 19篇 |
1982年 | 13篇 |
1981年 | 13篇 |
1980年 | 7篇 |
1979年 | 20篇 |
1978年 | 25篇 |
1977年 | 17篇 |
1976年 | 20篇 |
1975年 | 19篇 |
1974年 | 10篇 |
1972年 | 9篇 |
1967年 | 8篇 |
排序方式: 共有1597条查询结果,搜索用时 31 毫秒
1.
Monitoring left ventricular dilation in mice with PET. 总被引:3,自引:0,他引:3
Lars Stegger Klaus P Sch?fers Ulrich Fl?gel Lefteris Livieratos Sven Hermann Christoph Jacoby Petra Keul Edward M Conway Otmar Schober Jürgen Schrader Bodo Levkau Michael Sch?fers 《Journal of nuclear medicine》2005,46(9):1516-1521
Molecular imaging by small-animal PET is an important noninvasive means to phenotype transgenic mouse models in vivo. When investigating pathologies of the left ventricular (LV) myocardium, the serial assessment of LV volumes is important. By this, the presence of LV dilation as a sign of developing heart failure can be detected. Whereas PET is usually used to derive biochemical and molecular information, functional parameters such as ventricular volumes are generally measured using echocardiography or MRI. In this study, a novel method to monitor LV dilation in mice with PET is presented and evaluated using cardiac MRI. METHODS: A semiautomatic 3-dimensional algorithm was used to delineate the LV myocardial wall on static PET images depicting myocardial glucose metabolism ((18)F-FDG PET) for 20 mice: 10 wild-type and 10 genetically modified littermates designed to develop a dilative cardiomyopathy phenotype (cardiomyocyte-specific knockout of survivin). The volume enclosed by the 3-dimensional midmyocardial contour was calculated as a measure for LV volume for each mouse. Data were compared with ventricular volumes measured by MRI in the same animals. RESULTS: LV volumes obtained by PET and MRI correlated well (R = 0.89) for hearts with small and large left ventricles. In accordance with the hypothesis, the LV volumes were increased significantly for transgenic mice examined at an older age compared with those examined at a younger age (MRI: 160.5 +/- 25.7 microL vs. 114.7 +/- 15.2 microL [P = 0.012]; PET: 129.3 +/- 15.3 microL vs. 73.8 +/- 15.0 microL [P < 0.001], all values shown as mean +/- SD; for MRI, mean of end-diastolic and end-systolic volumes are given), whereas they did not for their wild-type littermates (MRI: 106.2 +/- 12.3 microL vs. 94.7 +/- 14.6 microL [P = 0.214]; PET: 82.6 +/- 20.9 microL vs. 65.0 +/- 16.9 microL [P = 0.185]). CONCLUSION: Evaluation and quantitation of LV dilation in both control and cardiomyopathic mice can be reliably and serially performed using small-animal PET and (18)F-FDG, yielding useful functional information in addition to metabolic data. 相似文献
2.
Anne Rannard Deborah Buck David E J Jones Oliver F W James Ann Jacoby 《Clinical gastroenterology and hepatology》2004,2(2):164-174
BACKGROUND AND AIMS: Assessment of health-related quality of life (HRQOL) is not routinely reported in the literature on chronic liver disease (CLD). Few studies have examined quality of life (QOL) in patients with primary biliary cirrhosis (PBC) despite its significant functional impact. One of the reasons for the lack of HRQOL measurement in patients with PBC may be the absence of a well-recognized and widely used measure that clinicians can use in ordinary clinical practice. The aim of this study is to evaluate HRQOL measures used in patients with PBC and examine the suitability of the measures for these patients. METHODS: A literature search identified reports that focused on any aspect of QOL in patients with PBC. Key texts were identified containing generic, domain-specific, and condition-specific measures. The identified measures were systematically evaluated for appropriateness, acceptability, reliability, validity, precision, and responsiveness. RESULTS: Twenty measures were identified from 9 key texts. Six of the measures were previously validated generic measures; 10 were domain-specific measures previously used to measure fatigue, depression, and psychological distress in general and psychiatric populations; and 4 measures had been developed in patients with CLD. Reporting of reliability and validity generally was consistent for all measures used. However, reporting of the remaining criteria was variable, particularly in relation to responsiveness over time and acceptability of the measures to patients with PBC. CONCLUSIONS: A clearer and more rigorous approach is needed in reporting the properties of HRQOL measures used in patients with PBC to help clinicians decide which measures are most suitable for these patients. 相似文献
3.
4.
Golli M; Van Nhieu JT; Mathieu D; Zafrani ES; Cherqui D; Dhumeaux D; Vasile N; Rahmouni A 《Radiology》1994,190(3):741
5.
6.
7.
8.
9.
Development of a Novel Scale to Assess Life Fulfilment as Part of the Further Refinement of a Quality-of-Life Model for Epilepsy 总被引:2,自引:1,他引:1
Summary: We have been involved in developing a health-related quality-of-life model for use as an outcome measure in epilepsy. As part of the further development of this model, we have developed a measure of life fulfilment. This scale is based on methods previously described by Krupinski in 1980. The value of Krupinski's approach is the opportunity for patients to weight the numerous aspects of their quality of life and assess the discrepancy between their actual and desired circumstances. The life fulfilment scale has been shown to be reliable (α= 0.7) and valid. The scale is currently being applied to several clinical studies in epilepsy. We believe that the scale provides a valuable contribution to our health-related quality-of-life model. 相似文献
10.
Plasmid-Determined AmpC-Type β-Lactamases 总被引:26,自引:0,他引:26